Cystoid Macular Edema, Uveitis
Conditions
Keywords
uveitis, macular edema, uveitis associated macular edema
Brief summary
The purpose of this study is to determine whether denufosol tetrasodium (INS37217) Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema.
Detailed description
Denufosol tetrasodium (INS37217) Intravitreal Injection may provide clinical benefit in treatment of uveitis associated macular edema (UME) by reducing retinal thickness as measured by OCT and possibly enabling recovery of vision loss associated with UME. Denufosol tetrasodium may also reverse the fluid accumulation of UME.
Interventions
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have anterior uveitis, intermediate uveitis, posterior uveitis or panuveitis in at least one eye * Have persistent macular edema and uveitis whose conditions are stable * Have no change in medication regimen for at least 3 months prior to randomization if currently taking medications such as immunosuppressive or anti-inflammatory agents; steroidal or non-steroidal agents (drops, oral or injected) * Have an OCT scan with a qualifying retinal thickness in the study eye * Have evidence of macular edema on OCT scan * Have at lease one eligible eye to be treated in the study based on visual acuity.
Exclusion criteria
* Have proliferative vitreoretinopathy greater than grade B * Have subretinal or vitreous hemorrhage, corneal opacity, or other conditions, which limit the view of the retina or obscure FA * Have uncontrollable elevated IOP, advanced, previous filtration surgery, or any current evidence of endophthalmitis in the study eye * Have ocular disorders in the study eye that may confound interpretation of study results * Have had cataract surgery in the study eye within 3 months, YAG laser capsulotomy within the past 1 month, or any other intraocular surgery within the past 90 days * Have pre-operative spherical equivalent refractive error of more than -10 diopters of myopia in the study eye * Have had any intravitreal or periocular injection or corticosteroids in the study eye during the 3 months prior to screening * Have any ocular implant device for the delivery of therapeutic agents to the eye * Be taking any excluded medications that could obscure or confound study results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the utility of denufosol in treating uveitis associated macular edema. | — |
| Evaluate the safety and tolerability of denufosol in subjects presenting with uveitis associated macular edema. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pilot study - not specified | — |
Outcome results
None listed